A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Study met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is ...

Bullous pemphigoid is a rare autoimmune disease that affects your skin. It’s a chronic disease that causes itchy, fluid-filled blisters to form all over your body. Although people of all ages, ...

Autoimmune bullous diseases comprise a group of conditions characterised by the formation of blisters on the skin and mucous membranes due to aberrant immune responses. Central to many of these ...

Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary ...